Live From AUA2024: Highlights in Bladder Cancer (2024)
Live from AUA2024: Highlights in Bladder Cancer will discuss the best in Bladder Cancer from the 2024 AUA Annual Meeting!
The AUA has designed this educational offering to increase the urologist’s understanding of how to translate the latest scientific advances into their routine clinical practice, improving the care of patients with bladder cancer, based on documented educational need. This activity will highlight content presented at the AUA2024 focused on bladder cancer, including the new newly released amendment to the AUA/SUO Guideline on Non-Muscle Invasive Bladder Cancer, novel therapies and the latest advances in bladder cancer care.
ACKNOWLEDGEMENT
This educational activity is supported by an independent educational grant from:
- Merck & Co., Inc.
Target Audience
- Urologists
- Urologists in training
- Non-physician providers involved in urology
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Discuss the newly released amendment to the AUA/SUO Guideline on Non-Muscle Invasive Bladder Cancer.
- Describe recent developments in the management of non-muscle invasive bladder cancer.
- Review current management approaches for non-metastatic muscle-invasive bladder cancer.
- Identify novel therapies and their mechanism of action in the management of advanced bladder cancer.
Education Council Disclosures
Education Council Disclosures_2024_01_25.pdf
COI Review Work Group Disclosures
COI Review Work Group Disclosures.pdf
Faculty Disclosures
Name | Company Name | Relationship Type | End Date |
Max Kates, MD | Fergene | Consultant or Advisor | Current |
Merck | Consultant or Advisor | Current | |
Pfizer | Consultant or Advisor | Current | |
Photocure | Consultant or Advisor | Current | |
Seagen/Astellas | Consultant or Advisor | Current | |
Jay Raman, MD | Nothing relevant to disclose |
AUA Staff have nothing to disclose.
All relevant financial disclosures have been mitigated.
Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Release Date: May 31, 2024
Expiration Date: May 31, 2025
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation